Prime Medicine, Inc. (PRME)
NASDAQ:PRME
Want to see PRME full AI Analyst Report?
PRME Stock Chart & Stats
$3.81
-$0.14(-4.27%)
At close: 4:00 PM EST
$3.81
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$1.41 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)2.76M
Market Cap
$501.21M
Enterprise Value$691.60M
Total Cash (Recent Filing)$135.50M
Total Debt (Recent Filing)$114.51M
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Aug 06, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding180,617,450
10 Day Avg. Volume2,906,596
30 Day Avg. Volume2,764,106
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue171.44
Enterprise Value/Gross Profit-15.83
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$7.80Price Target Upside104.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1
Revenue Forecast (FY)$12.93M
Bulls Say, Bears Say
Bulls Say
Proprietary Prime Editing PlatformPrime Medicine’s proprietary prime editing platform represents a durable competitive advantage: a differentiated, technology-led R&D foundation that can generate multiple therapeutic programs and licensing opportunities over years. As a platform play, it supports long-term optionality across indications and can create licensing, partnership, and program-level moat if clinical validation proceeds, reducing reliance on any single product outcome.
Collaboration And Licensing Revenue ModelA business model focused on collaboration, upfronts, milestones and royalties provides durable non-product-sale revenue channels that can fund R&D and de-risk development timelines. Robust partner-driven funding can extend runway and diversify financing sources, aligning incentives with collaborators and enabling steady capital inflows independent of immediate commercialization success.
Strengthened Financial Leadership And GovernanceHiring an experienced biotech finance executive as CFO and separating the CFO role from the CEO strengthens financial oversight and capital allocation capability. Improved governance and a seasoned CFO enhance credibility with investors and partners, support complex financing or licensing negotiations, and reduce operational governance risk over the medium term.
Bears Say
Persistent UnprofitabilityThe company’s large operating and net losses relative to modest revenue indicate structural profitability challenges. Persistent unprofitability erodes equity, constrains reinvestment capacity, and increases reliance on external funding. Unless clinical progress converts into scalable commercial revenue, losses are likely to continue pressuring long-term financial viability.
Weak Cash Generation And High BurnDeeply negative operating and free cash flows show the company is burning cash to fund R&D. High burn reduces runway, forces dilutive financings or costly debt, and limits strategic flexibility. Over 2-6 months this elevates execution risk and makes sustained program funding contingent on successful partnerships or capital raises.
Rising Leverage And Shrinking EquityA material increase in leverage and declining equity indicate worsening balance-sheet risk. Higher debt levels raise interest and covenant exposure, reduce flexibility for M&A or licensing investments, and increase refinancing needs. This structural shift constrains strategic options and amplifies downside if development setbacks occur.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.41 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $501.21M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on May 07, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.251 by -$0.029.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.26.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 180,617,450 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.251. Following the earnings report the stock price went down -8.651%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.80 (104.72% Upside)
$7.80 (104.72% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 780.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
90.06%
12-Months-Change
Fundamentals
Return on Equity
-188.82%
Trailing 12-Months
Asset Growth
-10.19%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$7.80
▲(104.72% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
46.79% Insiders
7.27% Mutual Funds
27.60% Other Institutional Investors
6.28% Public Companies and
Individual Investors